At the time of writing, Summit Therapeutics Inc [SMMT] stock is trading at $26.98, up 2.70%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 6.43% over the last week, with a monthly amount drifted -1.71%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Neutral rating and assigned the stock a price target of $21. Previously, UBS started tracking the stock with Buy rating on July 01, 2025, and set its price target to $30. On June 11, 2025, Leerink Partners initiated with a Underperform rating and assigned a price target of $12 on the stock. Citigroup upgraded its rating to a Buy and increased its price target to $35 on March 26, 2025. Cantor Fitzgerald initiated its recommendation with a Overweight. Evercore ISI started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $30. In a note dated February 28, 2025, Goldman initiated a Buy rating and provided a target price of $42 on this stock.
For the past year, the stock price of Summit Therapeutics Inc fluctuated between $11.76 and $36.91. Currently, Wall Street analysts expect the stock to reach $34.75 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $26.98 at the most recent close of the market. An investor can expect a potential return of 28.8% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.3, Equity is -2.09 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.47 points at the first support level, and at 23.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.27, and for the 2nd resistance point, it is at 31.56.
Ratios To Look Out For
It is important to note that Summit Therapeutics Inc [NASDAQ:SMMT] has a current ratio of 5.13. As well, the Quick Ratio is 5.13, while the Cash Ratio is 4.94.
